Valuation : DexCom, Inc.

Market Cap 33.17B 561B 28.53B 26.83B 24.49B 45.81B 3,137B 45.95B 318B 123B 1,606B 125B 122B 5,117B P/E 2026 *
35.2x
P/E 2027 * 29.6x
Enterprise Value 32.41B 548B 27.87B 26.21B 23.93B 44.75B 3,065B 44.9B 311B 120B 1,570B 122B 119B 5,000B EV / Sales 2026 *
6.2x
EV / Sales 2027 * 5.54x
Free-Float
91.27%
Yield 2026 *
-
Yield 2027 * -
1 day-0.57%
1 month+1.95%
3 months+23.14%
6 months+19.08%
Current year+26.05%
1 month 1,528
Extreme 1528
1,556.82
Current year 1,064.65
Extreme 1064.65
1,556.82
1 year 1,062.55
Extreme 1062.55
1,556.82
3 years 1,062.55
Extreme 1062.55
2,260
5 years 1,062.55
Extreme 1062.55
3,366.38
10 years 212.78
Extreme 212.775
3,366.38
Manager TitleAgeSince
Chief Executive Officer 47 2025-12-31
Director of Finance/CFO 46 2021-03-18
Chief Tech/Sci/R&D Officer - 2024-04-30
Director TitleAgeSince
Chairman 68 2018-07-29
Director/Board Member 67 2009-11-19
Director/Board Member 47 2025-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%-.--% - - 33.17B
-0.42%-3.68%-18.51%+6.67% 187B
+1.15%+3.22%+1.37%+16.68% 120B
-1.86%+2.77%+13.15%+89.47% 63.15B
+0.02%-1.07%+17.69%+45.19% 51.75B
-1.54%-2.52%-3.98%-30.72% 50.32B
-2.02%-3.22%+9.18%-17.76% 33.17B
0.00%+3.71% - - 32.1B
-0.81%+0.74%+35.59%-16.03% 23.93B
-2.41%-6.52%-10.28%+8.53% 22.99B
Average -0.85%-0.48%+5.53%+12.75% 65.03B
Weighted average by Cap. -0.48%-0.64%-1.52%+16.13%

Financials

2026 *2027 *
Net sales 5.23B 88.48B 4.5B 4.23B 3.86B 7.22B 495B 7.25B 50.16B 19.39B 253B 19.64B 19.21B 807B 5.8B 98.12B 4.99B 4.69B 4.28B 8.01B 549B 8.04B 55.62B 21.5B 281B 21.78B 21.3B 895B
Net income 974M 16.48B 838M 788M 719M 1.35B 92.15B 1.35B 9.34B 3.61B 47.19B 3.66B 3.58B 150B 1.15B 19.44B 988M 929M 848M 1.59B 109B 1.59B 11.02B 4.26B 55.65B 4.31B 4.22B 177B
Net Debt -761M -12.88B -655M -616M -562M -1.05B -71.98B -1.05B -7.3B -2.82B -36.86B -2.86B -2.8B -117B -1.06B -17.96B -913M -859M -784M -1.47B -100B -1.47B -10.18B -3.93B -51.41B -3.99B -3.9B -164B
Logo DexCom, Inc.
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 71.5% of net sales.
Employees
11,050
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
87.90USD
Average target price
94.12USD
Spread / Average Target
+7.08%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!